NAGE · Niagen Bioscience, Inc.

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the 38th Annual ROTH Conference , taking place at The Ritz-Carlton Laguna Niguel in Dana Point, California, from March 22 to 24, 2026. Niagen Bioscience CEO, Rob Fried, will participate in the Technologies Advancing Healthy Aging Panel on Monday, March 23, at 2:00 PM PT (5:00 PM ET). The panel will be livestreamed and available at www.event.summitcast.com . Additionally, Niagen Bioscience’s CEO, Rob Fried, and CFO, Ozan Pamir, will attend one-on-one meetings with institutional investors in person throughout the day. This year’s event will consist of one-on-one and small-group meetings, analyst-selected fireside chats, industry keynotes, and panels, with executive management from hundreds of private and public companies across a variety of growth sectors in attendance. Investors

By supporting investigator-initiated research worldwide, the program has helped establish Niagen Bioscience as a foundational force in advancing NAD+ understanding across the industry Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world. Rob Fried, CEO, Niagen Bioscience, commented, “Reaching more than 300 MTAs reflects the growing scientific momentum behind our patented nicotinamide riboside (NR) ingredient, Niagen ® . This program has contributed to 45 published clinical studies, making Niagen the most extensively researched patented NAD-boosting ingredient in the world. Across clinical and

Launch expands Niagen® into the growing skincare category through a limited-release model designed to generate consumer insights and inform future innovation Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of Niagen ® Skincare Innovation Lab , a new product innovation platform designed to translate the Company’s leadership in NAD+ science into category-defining skincare. Debuting under the platform is Niagen NanoCloud™ , a limited-release, dermatologist-tested topical skincare product powered by Niagen Bioscience’s flagship ingredient, Niagen ® (patented nicotinamide riboside, or NR), created to generate consumer insights and help shape future topical innovation within the Company’s core Tru Niagen ® portfolio. Niagen Bioscience Launches Niagen® Skincare Innovation Labs and Debuts Niagen NanoCloud™, the First Topical Product Powered by Patented Niagen® Rob

Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103% year-over-year to $17.4 million in 2025 Adjusted EBITDA increased 139% year-over-year to $20.4 million in 2025 Cash and cash equivalents totaled $64.8 million at December 31, 2025 compared to $44.7 million at December 31, 2024 Full year 2026 net sales outlook reflects between 10-15% growth, excluding the recently sold reference standards segment Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total net sales increased 16% to $33.8 million, with Tru Niagen® sales of $27.5 million, up 21% from the prior year quarter. Gross margin increased 160 basis points to 64.1%. Net income of $4.1 million compared to $7.2 million in the prior year quarter. Q4 2024 benefited from a $3.5 million reversal of